報價延遲最少15分鐘:2025/08/25 13:59 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.9 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-172.70/-0.43
|
|
企業價值
4.36M
|
| 資產負債 |
|
每股賬面淨值
50.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
203.00K
|
|
每股收益
0.81
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/25 13:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements. |
